Литература

1. Ball, J. C., Lange, W. R., et al. Reducing the risk of AIDS through methadone maintenance treatment. J. Health. Soc. Behav. 29:214-226, 1988.

2. Bell, J., Seres, V., et al. The use of serum methadone levels in patients receiving methadone maintenance. Clin. Pharmacol. Ther. 43:623-629, 1988.

3. Bickel, W. K., Johnson, R. E., et al. A clinical trial of buprenorphine: 1: Comparison with methadone in the detoxification of heroin addicts. II: Examination of its opioid blocking properties. Natl. Inst. Drug Abuse Res. Monogr. Ser. 76:182-188, 1987.

4. Cami, J., de Torres, S., et al. Efficacy of clonidine and of methadone in the rapid detoxification of patients dependent on heroin. Clin. Pharmacol. Ther. 38:336-341, 1985.

5. Carin, I., Glass, L., et al. Neonatal methadone withdrawal. Effects of two treatment regimens. Am. J. Dis. Child. 137:1166-1169, 1983.

6. Charney, D. S., Heninger, G. R., Kleber, H. D. The combined use of clonidine and naltrexone as a rapid, safe, and effective treatment of abrupt withdrawal from methadone. Am. J. Psychiatry 143:831-837, 1986.

7. Harding-Pink D. Methadone: One person's maintenance dose is another's poison. Lancet 341:665-666, 1993.

8. Jasinski, D. R., Johnson, R. E., Kocher, T. R. Clonidine in morphine withdrawal: Differential effects on signs and symptoms. Arch. Gen. Psychiatry 42: 1063-1066, 1985.

9. Johnson, R. E., Jaffe, J. H., Fudala, P. J. A controlled trial of buprenorphine for the treatment of opioid dependence. J.A.M.A. 267:2750-2755, 1992.

10. Kleber, H. D., Riordan, C. E., et al. Clonidine in outpatient detoxification from methadone maintenance. Arch. Gen. Psychiatry 42:391-394, 1985.

11. Kosten, T. R., Kleber, H. D. Buprenorphine detoxification from opioid dependence: A pilot study. Life Sci. 42:635-641, 1988.

12. Lerner, A. G., Sigal, M., et al. Naltrexone abuse potential. J. Nerv. Ment. Dis. (Israel) 180:734-735, 1992.

13. Mello, N. K., Mendelson, J. H., Kuehnle, J. C. Buprenorphine effects on human heroin self-administration: An operant analysis. J. Pharmacol. Exp. Ther. 223:30-39, 1982.

14. Pasternak, G. W. Opioid receptors. In H. Y. Meltzer (ed.), Psychopharmacology: The third generation of progress. New York: Raven, 1987, pp. 281-288.

15. Peachy, J. E. The role of drugs in the treatment of opioid addicts. Med. J. Australia 145:395-399, 1986.

16. Rosen, M. I., Kosten, T. R. Buprenorphine: Beyond methadone? Hosp. Comm. Psychiatry 42:347-349, 1991.

17. Rounsaville, B. J., Glazer, W., et al. Short-term interpersonal psychotherapy in methadone-maintained opiate addicts. Arch. Gen. Psychiatry 40:629-636, 1983.

18. Rounsaville, B. J., Kleber, H. D. Untreated opiate addicts. Arch. Gen. Psychiatry 42:1072-1077, 1985.

19. Senay, E. C. Methadone maintenance treatment. Int. J. Addict. 20:803-821, 1985.

20. Stimmel, B., Goldberg, J., et al. Ability to remain abstinent after methadone detoxification: A six-year study. J.A.M.A. 237:1216-1220, 1977.

21. Woods, J. H., Winger, G. Opioids, receptors, and abuse liability. In H. Y. Meltzer (ed.), Psychopharmacology: The third generation of progress. New York: Raven, 1987, pp. 1555-1564.

22. Woody, G. E., McLellan, A. T., et al. Twelve-month follow-up of psychotherapy for opiate dependence. Am. J. Psychiatry 144:590-596, 1987.

Авторы благодарят за ценные замечания Р. Мейера, участвовавшего в написании этой главы в первом издании "Психиатрии".

medznate.ru

^